Glucotrol and Alphagan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glucotrol (glipizide) and Alphagan (brimonidine tartrate). Common drug interactions include diabetic neuropathy among females and drug dependence among males.

The phase IV clinical study analyzes what interactions people have when they take Glucotrol and Alphagan. It is created by eHealthMe based on reports of 85 people who take the same drugs from the FDA, and is updated regularly.

What is Glucotrol?

Glucotrol has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 20,322 Glucotrol users. Check the latest studies of Glucotrol.

What is Alphagan?

Alphagan has active ingredients of brimonidine tartrate. It is often used in glaucoma. eHealthMe is studying from 9,981 Alphagan users. Check the latest studies of Alphagan.



On Aug, 02, 2026

85 people who take Glucotrol and Alphagan together, and have interactions are studied.

Glucotrol and Alphagan drug interactions.

What are the common drug interactions of Glucotrol and Alphagan, by gender? *:

female:

  1. Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
  2. Pancreatitis chronic (chronic inflammation of pancreas)
  3. Weight increased
  4. Blood pressure fluctuation
  5. Chest pain
  6. Dyspnoea (difficult or laboured respiration)
  7. Fall
  8. Polyp colorectal
  9. Rib fracture
  10. Suicidal behaviour

male:

  1. Drug dependence
  2. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
  3. Insomnia (sleeplessness)
  4. Pain
  5. Pyrexia (fever)
  6. Syncope (loss of consciousness with an inability to maintain postural tone)
  7. Weight decreased
  8. Abdominal pain
  9. Alanine aminotransferase increased
  10. Arthralgia (joint pain)

What are the common drug interactions of Glucotrol and Alphagan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  2. Abdominal pain
  3. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  4. Cerebrovascular disorder (disease of brain)
  5. Chest pain
  6. Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
  7. Fibromyalgia (a long-term condition which causes pain all over the body)
  8. Gastrointestinal pain
  9. Hypertension (high blood pressure)
  10. Non-cardiac chest pain

50-59:

  1. Weight decreased
  2. Anger
  3. Blood pressure increased
  4. Confusional state
  5. Drug ineffective
  6. Dyspepsia (indigestion)
  7. Heart rate increased
  8. Injection site haemorrhage (bleeding from injection site)
  9. Nervousness
  10. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)

60+:

  1. Fall
  2. Pain
  3. Cough
  4. Muscle spasms (muscle contraction)
  5. Syncope (loss of consciousness with an inability to maintain postural tone)
  6. Abdominal pain
  7. Alanine aminotransferase increased
  8. Arthralgia (joint pain)
  9. Aspartate aminotransferase increased
  10. Bereavement reaction

What are the existing conditions these people have? *

  1. Pain: 21 people, 24.71%
  2. Depression: 7 people, 8.24%
  3. High Blood Pressure: 6 people, 7.06%
  4. High Blood Cholesterol: 6 people, 7.06%
  5. Nausea And Vomiting: 5 people, 5.88%
  6. Intervertebral Disc Degeneration (spinal disc degeneration): 5 people, 5.88%
  7. Glossitis (infection of tongue with soreness): 5 people, 5.88%
  8. Dissociative Disorder: 5 people, 5.88%
  9. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Glucotrol and Alphagan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glucotrol and Alphagan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glucotrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Alphagan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glucotrol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Alphagan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on glipizide and brimonidine tartrate (the active ingredients of Glucotrol and Alphagan, respectively), and Glucotrol and Alphagan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: